SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• "Moderate Buy" consensus from eight analysts (2 sell, 5 buy, 1 strong buy) with an average 12‑month price target of $10.50.
• SAB is trading around $3.76 (12‑month range $1.05–$6.60) with a market cap of about $192M and reported an EPS miss of ($0.46) vs. ($0.16) consensus; analysts project roughly -3.69 EPS for the year.
• The company is a clinical‑stage biotech using the proprietary Tc Bovine® platform to generate fully human polyclonal antibodies, with lead programs focused on infectious diseases.

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight analysts that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $10.50.

A number of research analysts have commented on the stock. Chardan Capital lifted their price objective on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a "buy" rating in a research note on Wednesday, March 11th. Weiss Ratings restated a "sell (d)" rating on shares of SAB Biotherapeutics in a research note on Monday, December 29th. Rodman & Renshaw assumed coverage on shares of SAB Biotherapeutics in a research note on Thursday, April 2nd. They issued a "buy" rating and a $13.00 price objective on the stock. Zacks Research lowered shares of SAB Biotherapeutics from a "hold" rating to a "strong sell" rating in a research note on Thursday, March 12th. Finally, HC Wainwright dropped their price objective on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a "buy" rating on the stock in a research note on Tuesday, March 10th.

SAB Biotherapeutics Price Performance

Shares of NASDAQ:SABS opened at $3.76 on Wednesday. The company's fifty day moving average price is $3.99 and its 200 day moving average price is $3.57. SAB Biotherapeutics has a 12 month low of $1.05 and a 12 month high of $6.60. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.46 and a quick ratio of 9.46. The firm has a market capitalization of $191.57 million, a P/E ratio of -1.62 and a beta of 0.60.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last announced its quarterly earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.30). As a group, sell-side analysts predict that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. ADAR1 Capital Management LLC acquired a new position in SAB Biotherapeutics in the third quarter valued at $30,000. Dimensional Fund Advisors LP acquired a new position in SAB Biotherapeutics in the third quarter valued at $32,000. State of Wyoming purchased a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at about $34,000. Virtu Financial LLC purchased a new stake in shares of SAB Biotherapeutics in the third quarter valued at about $40,000. Finally, State Street Corp purchased a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at about $49,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.